BEIJING — China approved the registration applications of two domestically developed COVID-19 vaccines with conditions, the National Medical Products Administration said on Feb 25.

An inactivated vaccine from the Wuhan Institute of Biological Products, an affiliate of China National Biotec Group of Sinopharm, was allowed to enter the market on a conditional basis, the administration said.

The administration also conditionally approved the recombinant vaccine for COVID-19 made by CanSino Biologics. It marked the first approved adenoviral vector vaccine for COVID-19.